Domestic and multinational pharmaceutical companies have begun countdowns in the DDP-4 type anti-diabetes treatment market
DDP-4 (dipeptidyl peptidase-4) inhibitors, leading the diabetes treatment market, are expected to be shaken. Launched of DPP-4 inhibitor-type new drugs, such as adjusted lineup extensions, will be made.
Although the only DDP-4 inhibitor-type new drug is the LG Life Sciences’ Zemiglo Tab, fierce ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
